RxDoctor Payments Data

Keith Bopf, DPM

Podiatrist · Cape May Court House, NJNPI 1336213420

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations.

$5,873in general payments, 2019–2025

Across 84 payments — averaging $69.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$795
  • Smith+Nephew$591
  • Stryker$468
  • Bard Peripheral Vascular, Inc.$299
  • Kerecis Limited$286
  • AbbVie$269
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$5,873100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,873 in reported general payments places this provider in the 85th percentile of 382 podiatrist providers in New Jersey.

See all podiatrist providers in New Jersey

Medicare billing

Part B allowed, 2024
$195,520
Medicare patients
835
Services billed
4,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketoconazole45$1,042
Terbinafine Hcl56$656
Cefdinir24$255

Paid to pharmacies, not to this prescriber.

Other podiatrist in Cape May Court House

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →